Developing drugs that promote remyelination: Is our in vitro screening approach too simplistic?
Open Access
- 26 June 2024
- journal article
- research article
- Published by Elsevier in Neurotherapeutics
- Vol. 21 (4) , e00386
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialThe Lancet Neurology, 2019
- Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trialThe Lancet, 2017
- Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trialThe Lancet Neurology, 2017
- Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosisNature Medicine, 2014
- Blocking LINGO-1 as a Therapy to Promote CNS Repair: From Concept to the ClinicCNS Drugs, 2013
- Oligodendroglia metabolically support axons and contribute to neurodegenerationNature, 2012
- LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitisNature Medicine, 2007
- Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturationNature Medicine, 2005
- Interferon‐γ inhibits cell cycle exit in differentiating oligodendrocyte progenitor cellsGlia, 2005
- Chapter 40 The effect of drugs on oligodendrocyte proliferation and myelin regeneration1987